Business
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
FEATURED STORIES
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
It doesn’t matter how many times you have traversed Union Square; no one knows which way is north, or where The Westin is in relation to the Ritz Carlton. A Verizon outage brought that into focus on Wednesday.
Primarily known as an immunology and neuroscience company, AbbVie wanted to put the biopharma world on notice during its J.P. Morgan presentation: its oncology portfolio is underappreciated. This week, the Illinois-based company dove into the sizzling PD-1/VEGF space with a licensing deal with China-based RemeGen.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The AMR Action Fund financed two of this week’s money moves. Other moves ranged from medical devices to wearable sensor data companies. For that and more, continue reading.
Galen Robotics will further benefit from Robert Langer’s extensive experience in biotech startups and hands-on laboratory work.
Here’s a look at the eight most profitable biopharma companies around the world. Profitability, in this case, refers to net income, as opposed to total revenue or sales.
Boehringer Ingelheim made a splash on Tuesday, announcing its intention to pump €25 billion ($27 billion) into its R&D pipeline over the next five years.
Noted Harvard researcher Doug Melton is heading to Vertex Pharmaceuticals to head up investigations into potential transformative treatments for type 1 diabetes.
Athira Pharma is circling the wagons and urging shareholders to reject investor Richard Kayne’s calls for a management change.
Celeris Therapeutics and Boehringer Ingelheim (BI) have announced they are entering into a collaboration to develop next-generation targeted protein degraders.
With the close of these two funds, Andrew Schwab, managing partner at 5AM Ventures, said the firm has raised more than $2.2 billion to invest in the life sciences industry.
Following the ongoing trend in the pharmaceutical industry, approximately 30% of bluebird’s staff will be let go in an effort to reduce operational costs to under $340 million by the end of 2022.
Norman E. “Ned” Sharpless will step down from his role as director of the National Cancer Institute (NCI) at the end of this month, after serving in the role since 2017.